Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Assets (2016 - 2025)

Zevra Therapeutics' Other Non-Current Assets history spans 11 years, with the latest figure at $143000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 62.76% year-over-year to $143000.0; the TTM value through Dec 2025 reached $143000.0, down 62.76%, while the annual FY2025 figure was $143000.0, 62.76% down from the prior year.
  • Other Non-Current Assets reached $143000.0 in Q4 2025 per ZVRA's latest filing, down from $153000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q1 2024 to a low of $53000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $409526.3, with a median of $437000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 87.95% in 2023, then soared 1550.94% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $438000.0 in 2021, then tumbled by 87.9% to $53000.0 in 2022, then surged by 77.36% to $94000.0 in 2023, then surged by 308.51% to $384000.0 in 2024, then plummeted by 62.76% to $143000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Non-Current Assets are $143000.0 (Q4 2025), $153000.0 (Q3 2025), and $220000.0 (Q2 2025).